| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | EFFECT |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure
Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® |
| 05 Nov 2026 | D |
| 26 Oct 2026 | FORM S-1 |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of October 23, 2026 (this “Agreement”), by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and Traws Pharma, Inc., a Del... |
| 20 Oct 2026 | DEFA14A |
| 20 Oct 2026 | DEF 14A |
| 08 Oct 2026 | PRE 14A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for... |
| 16 Jul 2026 |
Form 4: Pauza Charles David, Chief Science Officer Virology
Granted 97,000 Stock Option (right to buy) |
| 15 Jul 2026 |
Form 4: Cautreels Werner, Director
Granted 14,150 Stock Option (right to buy) |
| 15 Jul 2026 |
Form 4: Savchuk Nikolay, Director
Granted 93,000 Stock Option (right to buy) |
Loading...